Skip to content
Menu

Zeev Bovan

688 posts

Posts (688)

Zeev Bovan NVDA 8 months ago #574

$TARA ?????

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events

Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026

Zeev Bovan TARA 8 months ago #575

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events

Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026

Zeev Bovan MSFT 8 months ago #576

It could tank towards 200$ along side all the mag 7 unless they would all declare that they would cut spending.

Zeev Bovan TARA 8 months ago #577

Bear trap, sometimes the sharks want more food and there is no better way then to scare retail investors who are mostly dumb and inexperienced.

Zeev Bovan TARA 8 months ago #578

These interim data are highly encouraging with respect to TARA-002’s efficacy and safety,” said Raj Satkunasivam, MD, MS, FRCSC, Urologic Oncologist, Associate Professor at Houston Methodist Hospital and ADVANCED-2 study investigator. “The results in the BCG-Unresponsive cohort demonstrate compelling six-month response rates with maturing 12-month data showing promising signals of durability. These clinically meaningful response rates and favorable tolerability profile make TARA-002 a potentially promising treatment option.”

“TARA-002 continues to demonstrate impressive and durable response rates with excellent safety and tolerability,” said Neal Shore, MD, FACS, Medical Director of the START Carolinas/Carolina Urologic Research Center. “These results, coupled with a clean safety profile and a simple, streamlined administration for both physicians and patients, make TARA-002 a potentially innovative new therapy for urologists, particularly those in busy community practices.”

Updated Interim Results

BCG-Unresponsive Cohort

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff.

The CR rate at any time was 65.7% (23 of 35)
The CR rate was 68.2% (15 of 22) at six months and 33.3% (5 of 15) at 12 months
Among responders:
The Kaplan-Meier (KM) estimated probability of maintaining a CR for six months was 71.1% (95% CI: 46.7, 95.5)
100% (5 of 5) maintained their CR from nine to 12 months
61.5% (8 of 13) of re-induced patients converted to a CR at six months
BCG-Naïve Cohort

The interim analysis of the BCG-Naïve cohort includes 29 evaluable participants, 27 of whom, were evaluable at six months and 19 were evaluable at 12 months as of a January 28, 2026 data cutoff.

The CR rate at any time was 72.4% (21 of 29)
The CR rate was 66.7% (18 of 27) at six months and 57.9% (11 of 19) at 12 months
Among responders:
The KM estimated probability of maintaining a CR for six months was 73.1% (95% CI: 52.9, 93.4)
100% (11 of 11) maintained their CR from nine to 12 months
66.7% (4 of 6) of re-induced patients converted to a CR at six months
Safety and Tolerability

The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient with no Grade 3 or greater TRAEs and no related serious adverse events as assessed by study investigators. No patients discontinued treatment due to TRAEs. The most common TRAEs were dysuria, bladder spasm, fatigue and micturition urgency. Most bladder irritations resolved shortly after administration or within a few hours to a few days.

“The data generated to date in these high-risk NMIBC patient populations highlight TARA-002’s potential as a meaningful addition to the treatment landscape,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “In addition to demonstrating impressive efficacy and safety, TARA-002 overcomes the limitations of existing NMIBC treatments that burden patients as well as urologists and their practices. We look forward to continuing to advance TARA-002’s clinical development as we work to bring this treatment to patients.”

Next Steps

Protara expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in the second half of 2026. Enrollment is complete in the BCG-Naïve cohort of the ADVANCED-2 trial with 31 patients, and the Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in the second half of 2026.

Zeev Bovan TARA 8 months ago #579

Smart money is position itself before the weak retail investors who sold/about to sell realise they have made a huge mistake, big whales took advantage of the dip and loaded on $TARA shares !

Zeev Bovan TARA 8 months ago #580

Ignorant idiots who can’t read reports are freaking out ?, never mind they will buy again at 10$ and then average up at 15$, take gains at 16$ just before it skyrockets above 30$!

$TARA ?????